

Development of Oseltamivir Phosphonate Congeners as Anti-influenza Agents

Ting-Jen R. Cheng,[†] Steven Weinheimer,[‡] E. Bart Tarbet,[§] Jia-Tsong Jan,[†] Yih-Shyun E. Cheng,[†] Jiun-Jie Shie,[†] Chun-Lin Chen,^{||} Chih-An Chen,^{||} Wei-Che Hsieh,^{||} Pei-Wei Huang,[⊥] Wen-Hao Lin,[⊥] Shi-Yun Wang,[†] Jim-Min Fang,^{*,†,||} Oliver Yoa-Pu Hu,^{*,⊥} and Chi-Huey Wong^{*,†}

[†]The Genomics Research Center, Academia Sinica, No. 128, Sec. 2, Academia Road, Taipei 11529, Taiwan

[‡]TaiMed Biologics, 5251 California Avenue, Suite 230, Irvine, California 92617, United States


[§]Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States

^{||}Department of Chemistry, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 106, Taiwan

[⊥]School of Pharmacy, National Defense Medical Center, No. 161, Sec. 6, Minquan E. Road, Taipei 114, Taiwan

S Supporting Information

ABSTRACT: Oseltamivir phosphonic acid (tamiphosphor, **3a**), its monoethyl ester (**3c**), guanidino-tamiphosphor (**4a**), and its monoethyl ester (**4c**) are potent inhibitors of influenza neuraminidases. They inhibit the replication of influenza viruses, including the oseltamivir-resistant H275Y strain, at low nanomolar to picomolar levels, and significantly protect mice from infection with lethal doses of influenza viruses when orally administered with 1 mg/kg or higher doses. These compounds are stable in simulated gastric fluid, liver microsomes, and human blood and are largely free from binding to plasma proteins. Pharmacokinetic properties of these inhibitors are thoroughly studied in dogs, rats, and mice. The absolute oral bioavailability of these compounds was lower than 12%. No conversion of monoester **4c** to phosphonic acid **4a** was observed in rats after intravenous administration, but partial conversion of **4c** was observed with oral administration. Advanced formulation may be investigated to develop these new anti-influenza agents for better therapeutic use.



INTRODUCTION

Influenza viruses infect humans every year through seasonal and pandemic infections due to the appearance of new influenza strains. For the prevention and treatment of influenza infections, vaccines and anti-influenza drugs are available. Though vaccines have been important for the protection of seasonal and pandemic influenza infections, the production needs to be started months before the onset of influenza infection. Furthermore, accurate prediction of the incoming influenza strains remains a major challenge. In the absence of an effective vaccine or for the treatment of influenza infections in unprotected individuals, anti-influenza drugs are needed.

Currently, the most effective anti-influenza drugs are neuraminidase (NA) inhibitors.^{1–3} Zanamivir (ZA) is the first marketed anti-influenza drug that is administered by inhalation or intranasal spray.^{4,5} The phosphate salt of oseltamivir (OS, **1b** in Figure 1), is the most popular orally available drug for influenza treatment.^{6,7} Oseltamivir is converted by endogenous esterase to oseltamivir carboxylate (OC, **1a**), which is the active inhibitor of influenza neuraminidase. Replacement of the amine group at the C-5 position with a more basic guanidino group (**2a**) shows better inhibitory activity than that of OC, presumably due to the stronger electrostatic interactions with the acidic residues

of Glu119, Asp151, and Glu 227 in the active site of influenza NA.⁶ However, compounds **2a** (GOC) and **2b** (GOS) have not been developed for therapeutic use. Two other anti-NA drugs, peramivir^{8,9} and laninamivir,^{10,11} were recently approved for use as intravenous and inhalation anti-influenza drugs, respectively. Due to the extensive use of oseltamivir in influenza therapy, oseltamivir-resistant viruses have emerged over the years. New anti-influenza drugs that can also inhibit oseltamivir-resistant strains, such as the H275Y mutant, are urgently needed for our battle against the threat of pandemic influenza.

We have recently discovered tamiphosphor (TP, **3a** in Figure 1),¹² an oseltamivir phosphonate congener, which is highly active for the inhibition of influenza neuraminidase and influenza virus replication. Replacement of the carboxylate group with the phosphonate group has resulted in a better binding to the neuraminidase and thus has become effective against the oseltamivir-resistant mutants. Moreover, guanidino-tamiphosphor (TPG, **4a**), derived by replacing the amino group at the C-5 position with a more basic guanidino group, can furthermore effectively inhibit the H275Y mutant of influenza neuraminidase.

Received: June 15, 2012




Figure 1. Chemical structures of anti-influenza agents.

As a continuing study on the development of TP and TPG as promising anti-influenza drugs, we report herein the pharmacological, including pharmacokinetic, properties of these compounds and their monoethyl esters TP1Et (**3c**) and TPG1Et (**4c**).

RESULTS

Synthesis of Oseltamivir Phosphonate Congeners. We have previously established methods for the synthesis of oseltamivir phosphonate congeners using *D*-xylose or bromobenzene as the starting material (Scheme 1).^{12,13} In brief, *D*-xylose was modified to intermediate **B**, bearing a diphosphonomethyl substituent at the C-5 position for the subsequent intramolecular Horner–Wadsworth–Emmons reaction to construct the scaffold of cyclohexenephosphonate (**C**). In another approach, microbial oxidation of bromobenzene provided the enantiopure bromoarene *cis*-1,2-dihydrodiol (**D**), which was elaborated by a series of functional group transformations to give an intermediate **F**. Substitution of the bromine atom in **F** with a phosphonate group was realized by a palladium-catalyzed coupling reaction to give compound **C**. Reduction of the azido group in **C** afforded TP diethyl ester (**3b**). Treatment of **3b** with bromotrimethylsilane gave the phosphonic acid **3a**, whereas treatment with sodium ethoxide afforded the monoester **3c**. By a similar procedure, the *N*²,*N*³-bis(*tert*-butoxycarbonyl) derivative of TPG diethyl ester (**4b**) was treated with bromotrimethylsilane to give TPG (**4a**) by concurrent removal of two diethyl groups and two *tert*-butoxycarbonyl groups. TPG monoester **4c** was obtained by consecutive treatments of **4b** with sodium ethoxide and acidic resin (Amberlite IR-120).

Inhibition of Influenza Neuraminidases. The structure-based design of NA inhibitors has been a successful strategy in discovery of anti-influenza drugs.¹⁴ According to the structural analysis, influenza NA interacts with the inhibitor, e.g.,


oseltamivir carboxylate (OC, **1a**), by strong electrostatic interactions of the carboxylate group with the three arginine residues (Arg118, Arg292, and Arg371) in the active site of NA. The phosphonate group was used as a bioisostere of carboxylate in drug design,^{15–17} because the phosphonate ion exhibits a stronger electrostatic interaction with the guanidinium ion.¹⁸ Consistent with this rationale, tamiphosphor (**3a**), containing a phosphonate group, was found to exhibit higher inhibitory activity than OC against various influenza viruses, including A/H1N1 (wild-type and H275Y mutant), A/H5N1, A/H3N2, and type B viruses (Table 1). As an ester, oseltamivir is inactive to NA. In contrast, TP monoester **3c** is active in NA inhibition because it still retains a negative charge at the phosphonate monoester group to provide sufficient electrostatic interactions with the three arginine residues in NA. Consistent with this rationale, the NA inhibitory activity of TP diethyl ester (**3b**) decreased dramatically ($IC_{50} > 3 \mu M$) against A/WSN/33 (H1N1) virus (data not shown).

The presence of an amino group at the C-5 position enhanced the affinity of OC to the residues of Glu119, Asp151, and Glu227 in the active site of NA.^{1–3} Replacing the C-5 amino group with a stronger base of guanidine should increase the electrostatic interactions with the acidic residues in the NA active site. Indeed, TPG (**4a**) showed an enhanced NA inhibitory activity in comparison with OC and ZA. Notably, TPG and its monoester **4c** also showed remarkable inhibitory activities against the H275Y oseltamivir-resistant strain with IC_{50} values of 0.4 and 25 nM, respectively.

Inhibition of Viruses in Cell Culture. The anti-influenza activities of phosphonate compounds **3a**, **3c**, **4a**, and **4c** were examined using a variety of influenza strains (Table 2). All four compounds are very potent anti-influenza agents with EC_{50} values ranging from low nanomolar to picomolar levels. Comparable anti-influenza activities were noted between the phosphonic acids and phosphonate monoesters (**3a** vs **3c**, and **4a** vs **4c**), even though the phosphonic acids were more potent NA inhibitors than the monoesters (Table 1). This result may be due to the improved lipophilicity of monoesters with enhanced intracellular uptake. We also noted that guanidino-tamiphosphor (**4a**) and its monoester **4c** were effective against the oseltamivir-resistant influenza strains in the cell-based assays. The anti-influenza cell protection activity of TPG monoester **4c** ($EC_{50} = 0.9–1.0 \mu M$) against oseltamivir-resistant influenza was more potent than oseltamivir ($EC_{50} > 10 \mu M$) by over 10-fold. With regard to toxicity, the potent anti-influenza agents **3a**, **3c**, **4a**, and **4c** were nontoxic to MDCK cells at the highest testing concentrations ($>100 \mu M$).

Animal Experiment against A/WSN/33 (H1N1) Virus. We then examined if the phosphonate compounds can protect mice from virus-induced mortality and weight loss. When compounds **3a**, **3c**, **4a**, and **4c** were administered orally to virus A/WSN/33-infected mice at 10 mg/kg/day, the mice survived and the weight recovered gradually 8 days after infection (Figure 2A and 2D). No significant protection was observed on treatment with the phosphonate diester **3b**, consistent with its low NA inhibitory activity due to the lack of an ionic phosphate moiety to interact with the three arginine residues in NA. Unlike OS which is readily subject to enzymatic hydrolysis to give active OC, there is no corresponding endogenous phosphotriesterase to cleave the diethyl groups in **3b**. When the infected mice were treated with test compounds at 1 mg/kg/day, TPG monoester **4c** showed better protection activity in mice survival than other compounds (Figure 2B and 2E). The phosphonate monoesters

Scheme 1. Outline for the Syntheses of Phosphonate Compounds 3a–3c and 4a–4c Using D-Xylose or Bromobenzene As the Starting Material (3a and 4a: R¹ = R² = H; 3b and 4b: R¹ = R² = Et; 3c and 4c: R¹ = H, R² = Et)^a



^aReagents and conditions:^{12,13} (i) Me₂CO, H₂SO₄, CuSO₄, 25 °C, 24 h; (ii) 0.05 M HCl, 50 °C, 1 h; 95% (two steps); (iii) Me₃CCOCl, pyridine, 0 °C, 8 h; 89%; (iv) pyridinium dichromate, Ac₂O, reflux, 1.5 h; HONH₂–HCl, pyridine, 60 °C, 24 h; 82%; (v) LiAlH₄, THF, 0 °C, then reflux 1.5 h; 88%; (vi) Ac₂O, pyridine, 25 °C, 3 h; HCl/1,4-dioxane (4 M), BnOH, toluene, 0–25 °C, 24 h; 85%; (vii) 2,2′-dimethoxypropane, toluene, cat. *p*-TsOH, 80 °C, 4 h; 90%; (viii) (CF₃SO₂)₂O, pyridine, CH₂Cl₂, –15 °C, 2 h; (ix) H₂C[PO(OEt)₂]₂, NaH, cat. 15-crown-5, DMF, 25 °C, 24 h; 73%; (x) H₂, Pd/C, EtOH, 25 °C, 24 h; (xi) EtONa, EtOH, 25 °C, 5 h, 80%; (xii) (PhO)₂PON₃, (*i*-Pr)₂N=C=N(*i*-Pr), PPh₃, THF, 25 °C, 48 h; (xiii) HCl, EtOH, reflux, 1 h; 74%; (xiv) (CF₃SO₂)₂O, pyridine, CH₂Cl₂, –15 to –10 °C, 2 h; (xv) KNO₂, 18-crown-6, DMF, 40 °C, 24 h; 71%; (xvi) Cl₃CC(=NH)OCH₂Et, CF₃SO₃H, CH₂Cl₂, 25 °C, 24 h; 82%; (xvii) H₂, Lindlar catalyst, EtOH, 25 °C, 16 h; giving **3b** (85%); (xviii) treating **3b** or **4b** with TMSBr, CHCl₃, 25 °C, 24 h; giving **3a** (85%) or **4a** (75%); (xix) treating **3b** or **4b** with EtONa, EtOH, 25 °C, 16 h; giving **3c** (82%) or **4c** (75%); (xx) treating **3b** with *N,N'*-bis(*tert*-butoxycarbonyl)thiourea, HgCl₂, Et₃N, DMF, 0–25 °C, 10–16 h; 58%; (xxi) CF₃CO₂H, CH₂Cl₂, 0 °C, 1 h; giving **4b** (72%); (xxii) *E. coli* JM109 (pDTG601), 37 °C, 3.5 h; 65%; (xxiii) 2,2′-dimethoxypropane, cat. H⁺, acetone, 0–25 °C, 0.5 h; (xxiv) *N*-bromoacetamide, cat. SnBr₄, H₂O, CH₃CN, 0 °C, 8 h; 75% (two steps); (xxv) (Me₃Si)₂NLi, THF, –10 to 0 °C, 0.5 h; (xxvi) 3-pentanol, BF₃·OEt₂, –10 to 0 °C, 6 h; 73% (two steps); (xxvii) conc. HCl, MeOH, 50 °C, 6 h; 94%; (xxviii) AcOCMe₂COBr, THF, 0–25 °C, 3.5 h; (xxix) LiBHET₃, THF, 0–25 °C, 2 h, 82% (two steps); (xxx) (PhO)₂PON₃, (*i*-Pr)₂N=C=N(*i*-Pr), PPh₃, THF, 40 °C, 24 h; 84%; (xxxi) diethyl phosphite, cat. Pd(PPh₃)₄, 1,4-diazabicyclo[2.2.2]octane, toluene, 90 °C, 12 h; giving compound **C** (83%).

Table 1. IC₅₀ Values (nM) of Influenza Neuraminidase Inhibition^a

virus	OC	ZA	3a	3c	4a	4c
A/WSN/33 (H1N1)	2.6 ± 1.4	2.9 ± 1.4	2.4 ± 0.8	3.0 ± 2.0	0.09 ± 0.05	1.1 ± 0.1
A/WSN/33/H275Y (H1N1) ^b	477 ± 181	1.6 ± 0.4	993 ± 666	1679 ± 43	0.4 ± 0.1	25.1 ± 6.6
NIBRG14 (H5N1)	0.73 ± 0.15	4.8 ± 0.2	0.52 ± 0.26	2.2 ± 0.6	0.04 ± 0.01	17.4 ± 8.6
A/Taiwan/3446/2002 (H3N2)	3.1 ± 0.9	13.8 ± 2.7	1.8 ± 0.06	5.9 ± 0.1	0.3 ± 0.06	131.7 ± 16.6
A/Udorn/1972 (H3N2)	2.9 ± 0.4	22.9 ± 7.8	1.6 ± 0.6	3.8 ± 1.1	0.35 ± 0.05	114 ± 20.3
B/Taiwan/70641/2004	36 ± 6.9	32.1 ± 8.4	73.6 ± 14	80.9 ± 12.7	2.1 ± 0.7	124.8 ± 32.4

^aA fluorescent substrate, 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA), was used to determine the IC₅₀ values that are compound concentrations causing 50% inhibition of different influenza neuraminidase enzymes. Data are shown as mean ± SD of three experiments.

^bA/WSN H275Y virus by oseltamivir selection.

3c and **4c** at 0.1 mg/kg/day can still exert partial protection (Figure 2C and 2F), indicating that these two compounds may have superior efficacy in the mouse infection model.

Animal Experiment against A/CA/04/2009 (H1N1, pandemic) Virus. Compounds **4a** and **4c** were further tested for their activities against pandemic influenza A (H1N1) virus A/CA/04/2009 infection in BALB/c mice. Both compounds were orally administered twice daily using 0.1, 1.0, and 10 mg/kg/day doses and were compared to groups of mice receiving water under the same treatment regimen. Mice were treated for 5 days beginning 4 h before virus exposure and observed for weight loss and mortality following virus challenge.

Figure 3 shows the survival results (**A**, **B**, and **C**) and weight changes (**D**, **E**, and **F**) following nasal virus challenge. The survivals of the groups treated with 10 and 1 mg/kg/day were significantly different from the control group (Figure 3A and 3B). However, the body weight recovery was slow and slight in mice treated with **4a** or **4c** at 10 mg/kg, while the body weight recovery was not observed in mice treated with either compound at 1 mg/kg (Figure 3D and 3E). In fact, low body weights persisted through day 20, and a number of mice died late in the study on days 20 and 21 (data not shown). For the group treated with compounds at 0.1 mg/kg/day, no significant protection was observed except a single mouse that rapidly recovered in the group treated with **4a** (Figure 3C and 3F).

Table 2. EC₅₀ Values (μ M) against Different Influenza Viruses Determined by Cytopathic Effect Inhibition Assays^a

virus	3a	3c	4a	4c
A/WSN/33 (H1N1)	0.084 \pm 0.016	0.047 \pm 0.004	0.36 \pm 0.283	0.18 \pm 0.014
A/CA/07/2009 (pandemic H1N1)	0.235 \pm 0.16	0.165 \pm 0.007	3.6 \pm 0.5	1.4 \pm 0.283
A/WSN/33/H275Y (H1N1) ^b	7.4 \pm 3.7	0.49 \pm 0.47	3.2 \pm 0.6	0.9 \pm 0.2
A/Hong Kong/2369/09/H275Y (pandemic H1N1)	6.55 \pm 0.36	0.44 \pm 0.09	4.6 \pm 2.7	1.0 \pm 0.22
A/Brisbane/10/2007 (H3N2)	>10	>10	>10	>10
A/Victoria/3/75 (H3N2)	0.043 \pm 0.04	0.041 \pm 0.05	0.035 \pm 0.04	0.034 \pm 0.04
A/Panama/2007/99 (H3N2)	0.008 \pm 0.001	0.002 \pm 0.005	0.007 \pm 0.0001	0.014 \pm 0.003
A/Duck/MN/1525/81 (H5N1)	0.007 \pm 0.0003	0.005 \pm 0.0006	0.475 \pm 0.049	0.2 \pm 0.004
B/Florida/4/2006	2.0 \pm 0.28	1.1 \pm 0	>10	>10
B/Sichuan/379/99	4.25 \pm 0.64	0.695 \pm 0.31	>10	>10

^aThe anti-influenza activities against different influenza strains were measured as EC₅₀ values that are the compound concentrations for 50% protection of the cytopathic effects due to the infection by different influenza strains. Data are shown as mean \pm SD of three experiments. ^bA/WSN reassortant H275Y virus.




Figure 2. Percentage of survival (A, B, C) and average body weight (D, E, F) of mice orally administered with test compounds at indicated concentrations twice per day and challenged with 10 \times LD₅₀ of A/WSN/33 (H1N1) influenza virus. The number of mice and the average weight of the mice at day 0 (10 mice per group) were defined as 100%, respectively. ***: $P < 0.0001$. **: $P < 0.001$. *: $P < 0.05$.

Animal Experiment against Oseltamivir-Resistant H275Y H1N1 Virus. We further examined if these four phosphonate compounds, 3a, 3c, 4a, and 4c, could protect mice against a challenge infection with an oseltamivir-resistant

influenza A (H1N1) virus A/WSN/33/H275Y in 10 \times LD₅₀. All four compounds and oseltamivir completely protected mice from death as well as weight loss at the 10 mg/kg/day dose (Figure 4A and 4D). At the dose of 1 mg/kg/day, significant protection to




Figure 3. Percentage of survival (A, B, C) and average body weight (D, E, F) of mice orally administered with various compounds at indicated concentrations and challenged with 1×10^5 ($3 \times \text{LD}_{50}$) cell culture infectious doses (TCID₅₀) of influenza A/CA/04/2009 (H1N1) virus. Mice were orally administered with test compounds 4 h prior to virus challenge and every day at a 12 h interval as indicated. The number of mice and the average weight of the mice at day 0 (10 mice per group) were defined as 100%, respectively. ***: $P < 0.0001$. **: $P < 0.001$.

improve mice survival was observed in the groups treated with phosphonates (3a, 3c, 4a, or 4c) compared to oseltamivir or water-treated mice (Figure 4B and 4E). No significant protection was noted by any compound treated at the dose of 0.1 mg/kg/day (Figure 4C and 4F). These data indicate that the phosphonate congeners are superior to oseltamivir in improving the survival of infected mice when challenged with oseltamivir-resistant influenza A (H1N1) viruses.

Animal Experiment against Avian Influenza H5N1 Virus. We also examined the dose–response effect of the compounds against a challenge infection with reassortant virus NIBRG-14, which contains HA and NA genes from the A/Viet Nam/1194/2004 (H5N1). At the dose of 10 mg/kg/day, significant protections were noted in mice treated with all tested oseltamivir phosphonate congeners compared to the mice treated with water (Figure 5A and 5D). No statistically significant differences were observed among these four treatment groups, though the phosphonate congeners showed an effect somewhat

more beneficial than that of oseltamivir. At the dose of 1 mg/kg/day compounds, the treated groups provided partial protection against virus challenge relative to the mice treated with water (Figure 5B and 5E). At the dose of 0.1 mg/kg/day, no treatment groups showed statistically significant protection (Figure 5C and 5F).

In summary, the mouse experiments demonstrated the antiviral efficacy of oseltamivir phosphonate congeners, especially the guanidino compounds 4a and 4c, by improving mouse survival at the dose of 10 or 1 mg/kg/day following challenge with A/WSN/33 (H1N1), A/CA/04/2009 (H1N1), A/WSN/33/H275Y (oseltamivir-resistant strain) or avian H5N1 influenza viruses.

Partition of Anti-influenza Compounds between Octanol and Phosphate Buffer. Lipophilicity is an important factor for the pharmacokinetic behavior of drugs. A measure of lipophilicity can be deduced from the partition coefficient (P) of a compound between octanol and water. Most oral drugs are




Figure 4. Survival (A, B, C) and body weight (D, E, F) of mice challenged with 10 \times LD₅₀ of oseltamivir-resistant influenza H275Y (A/WSN reassortant) virus. Mice were orally administered with test compounds 4 h prior to virus challenge and every day at a 12 h interval as indicated. ***: $P < 0.0001$. *: $P < 0.05$.

found to have log P values between -1 and 5 .¹⁹ In lieu of log P , the distribution coefficient (log D) is generally used to represent the partition of an ionic compound between octanol and PBS buffer. OC exhibits a high polarity with log D value of -1.50 at pH 7.4,²⁰ whereas OS is an oral drug with an improved lipophilicity (log $D = 0.36$) by changing the carboxylic group in OC to the ethyl ester. Table 3 shows the calculated and measured values of log D for a series of oseltamivir and phosphonate derivatives. All the diethyl and monoethyl ester derivatives with increased lipophilicity had log D values higher than those of their parent acids. Despite having double negative charges on the phosphonate group, tamiphosphor 3a (log $D = -1.04$) appeared to be less hydrophilic than OC (log $D = -1.69$), which carries a single negative charge. Interestingly, we also found that guanidino compounds 2a (log $D = -1.41$) and 4c (log $D = -0.37$) were more lipophilic than their corresponding amino compounds 1a (log $D = -1.69$) and 3c (log $D = -0.75$). This result was in agreement with the trend of calculation (clog D). The improved lipophilic property of 2a and 4c might be related to their zwitterionic structures, in which the C-5 guanidinium

could pair intramolecularly with the carboxylate or phosphonate (single-charged) groups.^{21,22}

Stability in Simulated Gastric Fluid. Compound 4c was stable in simulated gastric fluid (SGF, without enzymes), and 87% of 4c remained after incubation for 30 min at room temperature (data not shown). No apparent precipitation was observed. According to the LC/MS/MS analysis, there was no statistically significant difference by incubation in the presence or absence of SGF.

Metabolic Stability in Human, Dog, and Rat Whole Blood. TPG monoester 4c was found to be relatively stable in human, rat, and dog whole blood (Figure s1 in Supporting Information). No significant levels of free phosphonate metabolite 4a (m/z 363.4 [$M + H$]⁺) were found by using LC/MS/MS analysis.

Metabolic Stability in Human, Dog, and Rat Liver Microsomes. The metabolic stability of compound 4c was further tested in pooled human, male rat, and male dog liver microsomes (Table s1 in Supporting Information). No significant levels of the metabolite 4a (m/z 363.4 [$M + H$]⁺) were found by using LC/MS/MS analysis. The intrinsic




Figure 5. Survival (A, B, C) and average body weight (D, E, F) of mice challenged with $10\times$ LD₅₀ of NIBRG-14 A/Vietnam/1194/2004 (H5N1) influenza virus. Mice were orally administered with test compounds at indicated concentrations per day. ***: $P < 0.0001$. **: $P < 0.001$. *: $P < 0.05$.

Table 3. Distribution Coefficients of Anti-influenza Compounds between Octanol and PBS Buffer

entry	compound	clogP ^a	clogD ^b	log D ^c
1	1a (OC)	0.45	-1.84	-1.69 ± 0.16 (-1.50) ^d
2	1b (OS)	1.49	-0.72	(0.36) ^d
3	2a (GOC)	-0.22	-1.55	-1.41 ± 0.24
4	2b (GOS)	0.83	0.73	0.31 ± 0.05 ^e
5	3a (TP)	-1.25	-2.42	-1.04 ± 0.14
6	3b (TP2Et)	2.18	-1.39	0.22 ± 0.04
7	3c (TP1Et)	-0.14	-1.52	-0.75 ± 0.10
8	4a (TPG)	-1.92	-2.17	-0.98 ± 0.18
9	4b (TPG2Et)	1.51	-1.93	-0.10 ± 0.04
10	4c (TPG1Et)	-0.81	-1.27	-0.37 ± 0.02

^aCalculated values using Advanced Chemistry Development (ACD/Laboratories) Software V12.01. ^bCalculated values using MarvinSketch (<http://www.chemaxon.com/marvin/sketch/index.html>). ^cOctanol-water partition coefficient determined at pH 7.4 from five repeated experiments. ^dLog D value at pH 7.4 (adapted from ref 20). ^eLog D value at pH 7.4 (adapted from ref 22).

clearance (CL) of 4c was very low ($<2 \mu\text{L}/\text{min}/\text{mg}$ proteins), and the in vitro half-life ($t_{1/2}$) was long (>12 h). In contrast, the control compounds (testosterone and midazolam) were readily metabolized (65–100% in 1 h) in human, male rat, and male dog liver microsomes.

Metabolic Stability in Fresh Human Liver Microsomes.

Metabolic stabilities of the phosphonate compounds 3a, 3c, 4a, and 4c were tested in five fresh, pooled human liver microsome preparations using the cytochrome P450 (CYP) system (with cofactor NADPH) or the uridine 5'-diphospho-glucuronosyl-transferase (UGT) system (with cofactor UDPGA). The remaining levels of intact compounds 3a, 3c, 4a, and 4c were $107 \pm 8\%$, $92 \pm 3\%$, $92 \pm 7\%$, and $99 \pm 5\%$ in the CYP system at the end of the tests (1, 0.75, 1, and 0.5 h incubation, respectively), indicating no significant metabolism of any of the compounds by CYP enzymes. Compounds 4a and 4c were also stable in the UGT system, with $90 \pm 6\%$ and $91 \pm 3\%$ remaining of intact compounds, respectively, after 1 and 0.5 h incubation. The stabilities of compounds 3a and 3c in the UGT system were not tested.

Table 4. Pharmacokinetic Parameters of Test Compounds after Single iv Bolus or Oral Administration to Male Rats

PK parameter (unit)	3a		3c ^a	4a		4c	
	iv, 1 mg/kg (N = 6)	oral, 1 mg/kg (N = 6)	iv, 1 mg/kg (N = 6)	iv, 0.5 mg/kg (N = 6)	oral, 3 mg/kg (N = 6)	iv, 0.3 mg/kg (N = 6)	oral, 5 mg/kg (N = 6)
k (1/h)	0.213 ± 0.041	0.265 ± 0.127	0.428 ± 0.138	0.902 ± 0.251	0.485 ± 0.090	1.285 ± 0.037	0.669 ± 0.126
AUC _{0→t} (h*ng/ mL)	2620 ± 671	51.04 ± 28.95	1267 ± 336	666 ± 171	116.7 ± 54.5	389 ± 35	69.6 ± 10.2
AUC _{0→∞} (h*ng/ mL)	2634 ± 672	55.69 ± 25.51	1286 ± 344	669 ± 173	128.4 ± 59.4	390 ± 36	77.9 ± 10.3
t _{1/2} (h)	3.36 ± 0.63	3.05 ± 1.17	1.80 ± 0.72	0.83 ± 0.25	1.47 ± 0.24	0.54 ± 0.02	1.07 ± 0.21
CL/F (L/h/kg)	0.40 ± 0.10	22.10 ± 9.48	0.83 ± 0.25	0.79 ± 0.21	28.3 ± 13.4	0.77 ± 0.08	65.1 ± 8.3
V _d /F (L/kg)	1.87 ± 0.19	106.76 ± 73.43	2.29 ± 1.58	0.91 ± 0.21	59.6 ± 27.3	0.60 ± 0.06	100.9 ± 26.4
MRT (h)	1.47 ± 0.25	4.40 ± 0.64	1.44 ± 0.79	0.66 ± 0.06	2.40 ± 0.57	0.53 ± 0.03	2.05 ± 0.27
F (%)	100	2.33 ± 1.21	100	100	3.20 ± 1.48	100	1.20 ± 0.16
C _{max} (ng/mL)	—	12.92 ± 7.60	—	—	73.1 ± 81.7	—	25.8 ± 4.4
T _{max} (h)	—	1.46 ± 1.36	—	—	0.88 ± 0.21	—	1.38 ± 0.59

^aThe pharmacokinetic parameters for compound 3c in oral administration could not be deduced because its plasma concentrations were lower than the detection limit.

Table 5. Pharmacokinetic Parameters of Compounds 4a and 4c after Single iv Bolus or Oral Administration to Male Mice

PK parameter (unit)	4a		4c	
	iv, 0.25 mg/kg (N = 6)	oral, 10 mg/kg (N = 6)	iv, 0.25 mg/kg (N = 6)	oral, 10 mg/kg (N = 6)
k (1/h)	1.564 ± 0.729	0.300 ± 0.073	1.368 ± 0.625	0.364 ± 0.208
AUC _{0→t} (h*ng/mL)	354 ± 73	939 ± 346	529 ± 103	2575 ± 1441
AUC _{0→∞} (h*ng/mL)	373 ± 72	1050 ± 355	541 ± 108	2629 ± 1449
t _{1/2} (h)	0.53 ± 0.25	2.44 ± 0.61	0.71 ± 0.57	2.57 ± 1.54
CL/F (L/h/kg)	0.69 ± 0.12	10.30 ± 2.88	0.47 ± 0.08	4.75 ± 2.12
V _d /F (L/kg)	0.51 ± 0.18	36.04 ± 15.00	0.44 ± 0.24	20.00 ± 18.59
MRT (h)	0.58 ± 0.20	3.61 ± 0.81	0.63 ± 0.22	3.14 ± 0.60
F (%)	100	7.0 ± 2.4	100	12.1 ± 6.7
C _{max} (ng/mL)	—	337 ± 224	—	935 ± 536
T _{max} (h)	—	1.33 ± 0.52	—	1.38 ± 0.59

Table 6. Pharmacokinetic Studies in Rats and Dogs with Compound 4c in 20% HP-β-CD Aqueous Solution (iv administration) or in Microcrystalline Cellulose (oral administration)

PK parameter (unit)	rat		dog	
	iv, 2 mg/kg (N = 4)	oral, 50 mg/kg (N = 4)	iv, 5 mg/kg (N = 4)	oral, 20 mg/kg (N = 4)
k (1/h)	0.16 ± 0.01	0.31 ± 0.01	0.13 ± 0.03	0.13 ± 0.03
AUC _{0→t} (h*ng/mL)	3168 ± 492	4763 ± 1080	24516 ± 1918	11019 ± 2975
AUC _{0→∞} (h*ng/mL)	3170 ± 492	4610 ± 1053	24641 ± 1936	11561 ± 3210
t _{1/2} (h)	4.3 ± 0.28	2.2 ± 0.08	5.65 ± 1.30	5.50 ± 1.20
CL/F (L/h/kg)	0.64 ± 0.09	—	3.40 ± 0.27	—
V _d /F (L/kg)	0.33 ± 0.03	—	0.341 ± 0.015	—
MRT (h)	0.5 ± 0.03	5.6 ± 0.23	1.52 ± 0.139	5.12 ± 0.694
F (%)	100	6.0 ± 1.4	100	11.2 ± 2.73
C _{max} (ng/mL)	—	482 ± 153	—	2423 ± 591
T _{max} (h)	—	3.7 ± 3.9	—	1.50 ± 0.577

Protein Binding Measurements in Human, Rat, and Dog Plasma. Plasma protein binding of TPG monoester 4c in human, rat, and dog plasma was determined by rapid equilibrium dialysis followed by LC/MS/MS analysis. Compound 4c showed a high free fraction (86–91%) in plasma from all three species (Table s2 in Supporting Information). This result was consistent with the studies using microsome systems, which showed no significant conversion of the monoester 4c to the phosphonic acid metabolite 4a.

Pharmacokinetic Studies in Rats with Compounds Dissolved in Normal Saline. The pharmacokinetic parameters for compounds 3a, 3c, 4a, and 4c in Sprague–Dawley rats are listed in Table 4. After intravenous (iv) administration, the half-

lives of four compounds ranged from 0.54 to 3.36 h. The CL/F values ranged from 0.40 to 0.83 L/h/kg. After oral administration, the half-lives of compounds 3a, 4a, and 4c ranged from 1.07 to 3.05 h. The CL/F values of the three compounds ranged from 22.1 to 65.1 L/h/kg. The absolute oral bioavailabilities (F values) of compounds 3a, 4a and 4c were 2.33 ± 1.21%, 3.20 ± 1.48%, and 1.20 ± 0.16%, respectively. The plasma concentrations of compound 3c after oral administration were below the detection limit (Figure s2 in Supporting Information), so the corresponding pharmacokinetic parameters could not be deduced. This study indicated that the absolute oral bioavailability of all four compounds in normal saline was very low with relatively short half-lives in rats.

Pharmacokinetic Studies in Mice with Compounds in Normal Saline. Table 5 shows the pharmacokinetic parameters in mice. After iv administration, the half-lives of compounds **4a** and **4c** were 0.53 ± 0.25 and 0.71 ± 0.57 h, respectively. The CL/F values were 0.69 ± 0.12 and 0.47 ± 0.08 L/h/kg for compounds **4a** and **4c**, respectively. After oral administration, the half-lives of compounds **4a** and **4c** were 2.44 ± 0.61 and 2.57 ± 1.54 h, respectively. The CL/F values were 10.30 ± 2.88 and 4.75 ± 2.12 L/h/kg for compounds **4a** and **4c**, respectively. The oral bioavailability of compounds **4a** ($7.0 \pm 2.4\%$) and **4c** ($12.1 \pm 6.7\%$) in mice were appreciably higher than that in rats.

According to the plasma concentration–time curves for iv and oral administrations of compound **4a** to mice (Figure s3 in Supporting Information), the average concentration of **4a** in plasma at 8 h after oral administration was 31.4 ng/mL (~ 87 nM), which was higher than all EC_{50} values of the tested viruses. The average concentration of compound **4c** at 12 h was 16.8 ng/mL (~ 43 nM), which was also higher than the EC_{50} values of the tested viruses. These results might account for the high survival rates in the influenza-infected mice even though compounds **4a** and **4c** had only modest absolute bioavailability.

Pharmacokinetic Studies in Rats and Dogs with Compound 4c in 20% HP- β -CD Aqueous Solution or in Microcrystalline Cellulose. To investigate whether bioavailability of the test compound can be improved by adding pharmaceutical excipients, compound **4c** was dissolved in a 20% 2-hydroxypropyl- β -cyclodextrin (HP- β -CD) aqueous solution for iv administration or in microcrystalline cellulose for oral administration. A summary of the pharmacokinetic parameters determined in rats and dogs is shown in Table 6. After iv administration, the half-lives of compound **4c** in rat and dog were 4.3 and 5.65 h, respectively, with corresponding CL values of 10.7 and 3.4 mL/min/kg. After oral administration, the half-lives of compound **4c** in rat and dog were 2.2 and 5.5 h, respectively. The oral bioavailabilities of compound **4c** in rat and dog were 6.0% and 11.2%, respectively. No clear evidence of bioconversion of monoester **4c** to its free phosphonic acid **4a** was observed. Though the bioavailability of **4c** is not yet optimal for convenient oral dosing, this study indicates the possible improvement by formulation enhancements.

Excretion Study. After oral administration of compound **4c** (5 mg/kg) to rats, the recovery of phosphonate monoester **4c** from urine and feces was $1.5 \pm 0.4\%$ and $43.2 \pm 12.0\%$, respectively (Table s3 in Supporting Information). In the mean time, the free phosphonic acid **4a**, presumably a degradation product of **4c**, was also obtained from urine and feces at $0.4 \pm 0.2\%$ and $27.0 \pm 3.0\%$, respectively. The total recovery of compounds **4c** plus **4a** was estimated to be $1.9 \pm 0.5\%$ from urine and $70.2 \pm 12.1\%$ from feces.

Study of Acute Toxicity in Mice. Acute toxicity was studied in female Crl:CD1 (ICR) mice (20–30 g and 6–7 weeks old). Tamiphosphor (**3a**) dissolved in water-for-injection (WIF), with solubility up to 50 mg/mL, was administered by a single iv injection. TP monoester **3c** was suspended in carboxymethyl-cellulose (CMC) aqueous solution (0.5%, w/v) up to 30 mg/mL and applied by a single intraperitoneal (ip) injection. Acute toxicity was assessed by major clinical signs including tremor, convulsion, body jerks, hypoactivity, hunched posture, and piloerection (Table s4 in Supporting Information). Mortality in the treated animals occurred by iv dosing of tamiphosphor **3a** above 750 mg/kg or by ip dosing of tamiphosphor monoester **3c** at 2000 mg/kg. Clinical signs of acute toxicity which occurred in survivors were reversed within 2 days after dosing. No gross

lesions were observed upon necropsy of sacrificed animals after 15 days of study.

DISCUSSION

Tamiphosphor (**3a**), its monoester **3c**, guanidino-tamiphosphor (**4a**), and its monoester **4c** were synthesized and found to be potent inhibitors for influenza neuraminidases (Table 1). Phosphonates **3a** and **4a** are significantly more potent than their carboxylate congeners **1a** (OC) and **2a** (GOC) presumably due to the stronger binding of phosphonate with the three arginine residues (Arg118, Arg292, and Arg371) in the active site of NA. Unlike oseltamivir (**1b**), TP monoester **3c** and TPG monoester **4c** still possess effective NA inhibitory activities because the negative charge at the phosphonate monoester group provides the necessary electrostatic interactions with the three arginine residues in NA. Compounds **3a**, **3c**, **4a**, and **4c** inhibited the replication of different strains of influenza viruses at low nanomolar to picomolar levels (Table 2). In general, the phosphonate compounds **4a** and **4c**, bearing a guanidino group at the C-5 position, are more potent than the C-5 amino analogues **3a** and **3c** in inhibiting NA activity and virus replication of the oseltamivir-resistant viruses.

Owing to the intrinsic high anti-influenza activities, all four phosphonate compounds (**3a**, **3c**, **4a**, and **4c**) can significantly protect mice infected with several tested influenza strains (human H1N1, pandemic H1N1, H275Y H1N1 mutant, and avian H5N1) when administered at doses of 1 mg/kg/day or higher (Figures 2–5). Consistent with in vitro virus replication tests, the phosphonate congeners did show good protection against the challenge with oseltamivir-resistant A/WSN/33/H275Y virus.

The potent anti-influenza activity of tamiphosphor monoesters (**3c** and **4c**), nearly equal to that of the free phosphonic acids (**3a** and **4a**), may be surprising given that there was little evidence of bioconversion of the monoesters to the free phosphonic acids in metabolism studies. Perhaps the higher lipophilicity of monoester compounds resulted in higher intracellular concentrations of the compounds which, in turn, resulted in greater than expected anti-influenza activity. It has been shown that GOS (**2b**) having a guanidino group in lieu of the amino group in OS is no longer available to esterase digestion.²³ It is conceivable that guanidino-tamiphosphor monoethyl ester (**4c**) cannot be converted to the free acid **4a**; however, little bioconversion of **3c** is not expected. As the strategy used for laninamivir²⁴ and phospho-sulindac,²⁵ addition of a long aliphatic chain to phosphonate compounds **3a**, **3c**, **4a**, and **4c** may provide more efficient bioconversion, which is required to achieve higher levels of antiviral activity against oseltamivir-resistant influenza viruses.

The results presented in this study indicate that phosphonate compounds **3a**, **3c**, **4a**, and **4c** have similar pharmacokinetic properties (Tables 4–6). GOC (**2a**) was reported to have longer half-life (20.1 h) than OC (10.6 h) in rats.²³ In contrast, slight decrease in half-life of guanidino-tamiphosphor (**4a**) was found by replacement of the amino group in TP (**3a**) with a guanidino group. The compound half-lives were shorter than 4.5 h in rats and mice but slightly longer in dogs at about 5.5 h. The absolute oral bioavailability of all four compounds (as saline solutions) in rats was low ($\leq 3.20 \pm 1.48\%$). However, the oral bioavailability of compounds **4a** and **4c** in mice was higher (up to $12.1 \pm 6.7\%$) than in rats. Our study also indicates that formulation of **4c** in microcrystalline cellulose can improve its absolute oral bioavailability to 6% in rats and $11.2 \pm 2.73\%$ in dogs. Despite

low bioavailability, phosphonates **3a**, **3c**, **4a**, and **4c** can generally maintain the plasma concentrations in mice above the concentration required to inhibit the influenza viruses (Table S2 in Supporting Information), consistent with the observed protection against lethal infection in mice. As the level of plasma protein binding was low, the circulating compound would be almost entirely free of bound protein and available to exert antiviral activity *in vivo*.

On the basis of the *in vitro* metabolism studies, none of the phosphonate compounds are metabolized extensively by CYP or UGT enzymes *in vivo* nor is there evidence of bioconversion of phosphonate monoesters to free phosphonic acids in liver microsomes or whole blood. These findings are consistent with the observation in pharmacokinetic studies, which showed negligible accumulation of phosphonic acid **4a** after administration of monoester **4c**. After oral administration, in fact, most of **4c** (43%) and its degradation product **4a** (27%) were excreted in feces. Thus, compound **4c** might be biotransformed to **4a** in gastrointestinal tract extensively. The low oral bioavailability of **4c** may be due to incomplete absorption as well as partial biotransformation to **4a** in gastrointestinal tract.

As shown in this study, substitution of the carboxylate in OC (**1a**) by phosphonate, giving tamiphosphor **3a**, and further substitution of the amine by guanidine, giving TPG **4a**, all provide better affinity to influenza neuraminidases, and thus enhance the potency against influenza viruses. However, incorporation of the charged phosphate and guanidinium ions in **3a** and **4a** also causes problem in pharmacokinetics. Poor absolute oral bioavailability (<5%) has also been encountered in the anti-influenza agents OC (4.3%), guanidino-OC (**2a**, 4.0%) and zanamivir (3.7%).²³ The problem in OC has been solved by preparation of its ethyl ester (OS) as a prodrug with good oral bioavailability (35%) and high peak concentration (C_{\max} = 0.47 $\mu\text{g/mL}$) in plasma.²⁶ Formulation of the OS phosphate salt with appropriate filler materials further improves its bioavailability to 79% for marketing as the tamiflu capsule. The half-life and bioavailability of compounds **3a** and **4a** are comparable to that of ZA (1.8 h and 3.7%).²³ To develop **3a** and **4a** with nonoral administration is possible.²⁷

As the first approach to improve the pharmacokinetic properties of tamiphosphor **3a** and TPG **4a**, we synthesized the monoethyl ester derivatives **3c** and **4c** to investigate their pharmaceutical properties. Compound **4c** (as the saline solution) did show better bioavailability (F = 12%) than **4a** (F = 7%) in mice but not in rats. Using microcrystalline cellulose as the excipient, the bioavailability of **4c** was appreciably improved in rats and was nearly 12% in dogs. It seems promising to design other tamiphosphor prodrugs using varied monoesters to attain better bioconversion and biopharmaceutical properties.²⁸ In contrast, to develop positively charged guanidine-containing compounds into orally available drugs is still a challenging task.²⁹ Even so, considerable progress has been made to improve the permeability and possible oral bioavailability of ZA, for example, by encapsulation with liposome,³⁰ by ion-pairing with 2-hydroxynaphthoic acid,²¹ and by a prodrug moiety targeting intestinal membrane carriers.³¹ These new strategies and mechanisms of advanced formulation and structural modification for enhancing oral bioavailability of phosphate- and guanidine-containing compounds may be applied to develop highly potent anti-influenza agents **4a** and **4c** for practical therapeutic use.

EXPERIMENTAL SECTION

Materials and Methods. Nicotinamide adenine dinucleotide phosphate (NADP⁺), glucose-6-phosphate (G6P), glucose-6-phosphate dehydrogenase (G6PD), magnesium chloride, uridine 5'-diphosphoglucuronic acid (UDPGA), and alamethicin were purchased from Sigma. Phosphate buffer was prepared from potassium dihydrogenphosphate (KH₂PO₄) purchased from Nacalai Tesque Incorporation. Acetonitrile and methanol were purchased from J. T. Baker, and formic acid was from Sigma-Aldrich. The solution of NH₄OH (5%) in MeOH was purchased from Fluka. The reagents for cell culture including DMEM (Dulbecco's modified Eagle medium), fetal bovine serum, and penicillin–streptomycin were purchased from Invitrogen (Carlsbad, CA).

All the reagents were commercially available and used without further purification unless indicated otherwise. All solvents were anhydrous grade unless indicated otherwise. All nonaqueous reactions were carried out in oven-dried glassware under a slight positive pressure of argon unless otherwise noted. Reactions were magnetically stirred and monitored by thin-layer chromatography on silica gel. Flash chromatography was performed on silica gel of 60–200 μm particle size. Melting points were recorded on an Electrothermal MEL-TEMP 1101D melting point apparatus and were not corrected. NMR spectra were recorded on Bruker AVANCE 600 and 400 spectrometers. Chemical shifts are given in δ values relative to tetramethylsilane (TMS); coupling constants J are given in hertz. Internal standards were CDCl₃ (δ_{H} = 7.24), MeOH-*d*₄ (δ_{H} = 3.31), or D₂O (δ_{H} = 4.79) for ¹H NMR spectra, CDCl₃ (δ_{C} = 77.0) or MeOH-*d*₄ (δ_{C} = 49.15) for ¹³C NMR spectra, and H₃PO₄ in D₂O (δ_{P} = 0.00) for ³¹P NMR spectra. The splitting patterns are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), and dd (double of doublets). IR spectra were recorded on a Thermo Nicolet 380 FT-IR spectrometer. Optical rotations were recorded on a Perkin-Elmer Model 341 polarimeter. High resolution ESI mass spectra were recorded on a Bruker Daltonics spectrometer.

Oseltamivir carboxylic acid (**1a**, OC), oseltamivir (**1b**, OS, tamiflu as the phosphate salt), guanidino-OC (**2a**, GOC), guanidino-OS (**2b**, GOS), zanamivir (ZA, Relenza), and the oseltamivir phosphonate congeners including tamiphosphor (**3a**, TP), tamiphosphor diethyl ester (**3b**, TP2Et), guanidino-tamiphosphor (**4a**, TPG), and guanidino-tamiphosphor diethyl ester (**4b**, TPG2Et) were prepared in our laboratory according to the previously reported procedures.^{12,13} The synthetic procedures for tamiphosphor monoethyl ester (**3c**, TP1Et) and guanidino-tamiphosphor monoethyl ester (**4c**, TPG1Et) are described as follows. Purity of these compounds was assessed to be $\geq 95\%$ by HPLC analyses (Agilent 1100 series) on an HC-C18 column (5 μm porosity, 4.6 \times 250 mm) using MeOH/H₂O (1:1) as the eluent and UV detector at λ = 214 nm.

Tamiphosphor Monoethyl Ester (3c). A solution of tamiphosphor diethyl ester **3b** (1.43 g, 3 mmol) in ethanol (50 mL) was treated with sodium ethanoate in ethanol (4.5 mmol, 4.5 mL of 1 M solution) under a nitrogen atmosphere. The mixture was stirred for 16 h at room temperature and then acidified with Amberlite IR-120 (H⁺-form). The heterogeneous solution was stirred at 40 °C for 2 h, filtered, and concentrated *in vacuo*. The residual oil was taken up in water (15 mL) and subjected to lyophilization. The residual colorless solids were washed with cold acetone (20 mL \times 3), dissolved in aqueous NH₄HCO₃ (15 mL of 0.1 M solution), stirred for 1 h at room temperature, and then lyophilized to afford the ammonium salt of TP monoethyl ester **3c** (898 mg, 82%) as white solids. The purity of product was >98% as shown by HPLC on an HC-C18 column (Agilent, 4.6 \times 250 mm, 5 μm) with elution of MeOH/H₂O (50:50), t_{R} = 7.5 min (UV detection at 214-nm wavelength). C₁₅H₃₂N₃O₅P, mp 65–67 °C; $[\alpha]_{\text{D}}^{20}$ = –36.2 (c = 0.7, H₂O); IR (neat) 3503, 3211, 2921, 1714, 1658, 1121 cm^{–1}; ¹H NMR (600 MHz, D₂O) δ 6.33 (1 H, d, $J_{\text{P-2}}$ = 19.2 Hz), 4.23 (1 H, d, J = 9.4 Hz), 3.99 (1 H, dd, J = 10.2, 5.1 Hz), 3.86–3.84 (2 H, m), 3.53 (1 H, br s), 3.48–3.45 (1 H, m), 2.76–2.73 (1 H, m), 2.41–2.37 (1 H, m), 2.07 (3 H, s), 1.61–1.40 (4 H, m), 1.24 (3 H, t, J = 6.8 Hz), 0.89 (3 H, t, J = 7.1 Hz), 0.84 (3 H, t, J = 7.1 Hz); ¹³C NMR (150 MHz, D₂O) δ 175.1, 136.4, 130.3 (C-1, d, $J_{\text{P-1}}$ = 168 Hz), 84.2, 76.2, 76.1, 61.3, 53.6, 49.6, 29.9, 25.5,

25.2, 22.3, 15.8, 8.5; ^{31}P NMR (242 MHz, D_2O) δ 12.89; HRMS calcd for $\text{C}_{15}\text{H}_{28}\text{N}_2\text{NaO}_5\text{P}$ [$\text{M} + \text{Na} - \text{NH}_4$] $^+$: 370.1639, found: m/z 370.1643.

Guanidino-tamiphosphor Monoethyl Ester (4c). By a procedure similar to that for compound 3c, TPG diethyl ester 4b (2.73 g, 4 mmol) was treated with sodium ethanoate in ethanol, followed by workup using Amberlite IR-120 and ion exchange with NH_4HCO_3 , to give the ammonium salt of TPG monoethyl ester 4c (1.22 g, 75%) as white solids. The purity of product was >98% as shown by HPLC on an HC-C18 column (Agilent, 4.6×250 mm, $5 \mu\text{m}$) with elution of $\text{MeOH}/\text{H}_2\text{O}$ (50:50), $t_{\text{R}} = 7.9$ min (UV detection at 214-nm wavelength). $\text{C}_{16}\text{H}_{34}\text{N}_5\text{O}_5\text{P}$, mp 70–72 °C; $[\alpha]_{\text{D}}^{20} = -11.5$ ($c = 0.6$, H_2O); IR (neat) 3521, 1931, 1756, 1623, 1210 cm^{-1} ; ^1H NMR (600 MHz, D_2O) δ 6.29 (1 H, d, $J_{\text{P},2} = 19.1$ Hz), 4.25–4.22 (1 H, m), 3.91–3.82 (4 H, m), 3.51 (1 H, br s), 2.57–2.55 (1 H, m), 2.242.20 (1 H, m), 2.01 (3 H, s), 1.63–1.49 (3 H, m), 1.44–1.40 (1 H, m), 1.24 (3 H, t, $J = 6.9$ Hz), 0.88 (3 H, t, $J = 7.0$ Hz), 0.82 (3 H, t, $J = 7.0$ Hz); ^{13}C NMR (150 MHz, D_2O) δ 174.5, 160.3, 136.5, 131.8 (C-1, d, $J_{\text{P},1} = 171$ Hz), 84.2, 76.9, 76.8, 61.2, 55.6, 51.0, 31.6, 25.6, 25.3, 22.0, 15.7, 8.5; HRMS calcd for $\text{C}_{16}\text{H}_{30}\text{N}_4\text{NaO}_5\text{P}$ ($\text{M} + \text{Na} - \text{NH}_4$) $^+$: 412.1857, found: m/z 412.1859.

Viruses. Influenza A/WSN/33 (H1N1) viruses was obtained from Dr. Shin-Ru Shih (Chang Gung University in Taiwan) or from Dr. Kenneth Cochran (University of Michigan, Ann Arbor). A/Taiwan/3446/2002 (H3N2) and B/Taiwan/70641/2004 were gifts from Dr. Shin-Ru Shih (Chang Gung University in Taiwan). The reassortant H5N1 virus NIBRG14 created with hemagglutinin as well as neuraminidase genes from A/Vietnam/1194/2004, and the other genes from PR8 were originally from National Institute for Biological Standards and Control (Hertfordshire, UK). Influenza A/California/07/2009 (H1N1, Pandemic), A/Brisbane/10/2007 (H3N2), and A/Udorn/1972 (H3N2) were obtained from Centers for Disease Control (Taiwan). The oseltamivir-resistant A/WSN H275Y mutant was created using a 12-plasmid system that is based on cotransfection of mammalian cells with 8 plasmids encoding virion sense RNA under the control of a human PolI promoter and 4 plasmids encoding mRNA encoding the RNP complex (PB1, PB2, PA, and nucleoprotein gene products) under the control of a PolII promoter.^{32,33} An H275Y mutation was introduced in the NA gene, and the sequence was confirmed to generate the A/WSN H275Y virus. Alternatively, the oseltamivir-resistant WSN mutant was selected by six passages in Madin-Darby canine kidney (MDCK) cells with gradually increased OC (oseltamivir carboxylate) concentrations. This mutant influenza grows well in the presence of 1 μM OC and carries a single H275Y mutation at its NA gene as confirmed by sequence analysis. Influenza A/Panama/2007/99 (H3N2), A/Hong Kong/2369/2009 (H275Y, oseltamivir-resistant H1N1), B/Florida/4/2006, and B/Sichuan/379/99 viruses were obtained from the Centers for Disease Control and Prevention (Atlanta, GA). Influenza A/Victoria/3/75 (H3N2) virus was purchased from the American Type Culture Collection (Manassas, VA). Mouse-adapted influenza A/California/04/2009 (H1N1) and A/Duck/MN/1525/81 were kindly provided by Drs. Elena Govorkova and Robert Webster (St Jude Children's Research Hospital, Memphis, TN), respectively. All viruses were cultured in the allantoic cavities of 10-day-old embryonated chicken eggs for 72 h and purified by sucrose gradient centrifugation. In another preparation, A/California/04/2009 (H1N1) virus was adapted to replication in the lungs of BALB/c mice by nine sequential passages through mouse lungs. Virus was plaque-purified in MDCK cells, and a virus stock was prepared by growth in embryonated chicken eggs and then MDCK cells.

Determination of Influenza Virus TCID₅₀. MDCK cells were obtained from American Type Culture Collection (Manassas, VA), and were grown in DMEM containing 10% fetal bovine serum and penicillin–streptomycin at 37 °C under 5% CO_2 . The TCID₅₀ (50% tissue culture infectious dose) was determined by incubation of serially diluted influenza virus in 100 μL solution with 100 μL of MDCK cells at 1×10^5 cells/mL in 96-well microplates. The infected cells were incubated at 37 °C under 5% CO_2 for 48–72 h and added to each well with 100 μL per well of CellTiter 96 AQ_{ueous} Non-Radioactive Cell Proliferation Assay reagent (Promega). After incubation at 37 °C for 15

min, absorbance at 490 nm was read on a plate reader. Influenza virus TCID₅₀ was determined using the Reed–Muench method.^{34,35}

Determination of IC₅₀ of Neuraminidase Inhibitors. The neuraminidase activity was measured using either fluorogenic or luminescence substrate. In one approach, the neuraminidase activity was measured using diluted allantoic fluid harvested from influenza virus-infected embryonated eggs and a fluorogenic substrate 2'-(4-methylumbelliferyl)- α -D-N-acetylneuraminic acid (MUNANA; Sigma). For the inhibition test, the compound of interest was incubated with diluted virus-infected allantoic fluid for 10 min at room temperature followed by the addition of 200 μM substrate. The fluorescence of the released 4-methylumbelliferone was measured in Envision plate reader (Perkin-Elmer, Wellesley, MA) using excitation and emission wavelengths of 365 and 460 nm, respectively. The inhibitor IC₅₀ values were determined from the dose–response curves by plotting the percent inhibition of NA activity versus inhibitor concentrations using Prism 5 (GraphPad Software, Inc., San Diego, CA).

Alternatively, the effect of inhibitor on viral NA activity was performed using a commercially available kit with a chemiluminescent substrate of sialic acid 1,2-dioxetane derivative (NA-Star Influenza Neuraminidase Inhibitor Resistance Detection Kit, Applied Biosystems, Foster City, CA) in 96-well solid white microplates following the manufacturer's instructions. Inhibitor in half-log dilution increments was incubated with virus (as the source of neuraminidase). The amount of virus in each microwell was approximately 500 cell culture infectious doses (CCID₅₀). Plates were preincubated for 10 min at 37 °C prior to addition of chemiluminescent substrate. Following addition of substrate, plates were incubated for 30 min at 37 °C. The NA activity was evaluated using a Centro LB 960 luminometer (Berthold Technologies) for 0.5 s immediately after addition of NA-Star accelerator solution. Fifty percent inhibitory concentrations (IC₅₀ values) of viral NA activity were determined by plotting percent chemiluminescent counts versus log₁₀ of the concentration of inhibitor.

Determination of EC₅₀ of Neuraminidase Inhibitors. The anti-influenza virus activities of NA inhibitors were measured by the EC₅₀ values, i.e., the concentrations of the compound required for 50% protection of the influenza virus infection-mediated cytopathic effects (CPE). A 50–100 μL amount of diluted influenza virus (100 TCID₅₀) was mixed with equal volumes of NA inhibitors at varied concentrations. The mixtures were then used to infect 100 μL of MDCK cells at 1×10^5 cells/mL in 96-well plates. After 48–72 h incubation at 37 °C under 5% CO_2 , the CPE were determined with CellTiter 96 AQ_{ueous} Non-Radioactive Cell Proliferation Assay reagent, as described above, or alternatively with 0.11 final percentage of neutral red for 2 h. Inhibitor EC₅₀ values were determined by fitting the curve of percent CPE versus the concentrations of NA inhibitor using Graph Pad Prism 4.

Animal Experiments for Virus Challenges. Female BALB/c mice (18–20 g) were obtained from Charles River Laboratories or National Laboratory Animal Center (Taiwan). The mice were quarantined for 48–72 h before use. The mice were anesthetized by intraperitoneal (ip) injection of zoletil (or ketamine/xylazine) and inoculated intranasally with 25 μL of infectious influenza virus. The test compounds were dissolved in sterile water and administered to mice at the indicated dosages by oral gavage (po) twice daily for 5 days. Control mice received sterile water on the same schedule. Ten mice per test group were used throughout the studies. Four hours after the first dose of drug, mice were inoculated with influenza virus at 3–10 \times mouse LD₅₀, depending upon the virus strain. Mice were observed daily for 14–21 days for survival and body weight.

Statistical Analysis. Kaplan–Meier survival curves were generated and compared by the Log-rank (Mantel–Cox) test using Prism 5.0b (GraphPad Software Inc.). Where statistical significance was seen, pairwise comparisons were made by the Gehan–Breslow–Wilcoxon test. Mean body weights were analyzed by ANOVA followed by Tukey's multiple comparison test using Prism 5.0b. For stability studies in gastric fluid and fresh human liver microsomes, and pharmacokinetic study with compound in normal saline, the Microsoft Excel 2002 (e.g., mean, SD, % CV, % diff) and SPSS 13.0 software (ANOVA and linear regression) were used.

Ethical Regulation of Laboratory Animals. This study was conducted in accordance with the approval of the Institutional Animal Care and Use Committee of Utah State University dated Sept 20, 2010 (expires Sept 19, 2013), or the Institutional Animal Care and Use Committee, National Defense Medical Center, Taiwan (2009–2011), or the Institutional Animal Care and Use Committee, Academia Sinica, Taiwan. The work was done in the AAALAC-accredited Laboratory Animal Research Center of Utah State University, or in the AAALAC-accredited Animal Center of National Defense Medical Center, or in the BSL-3 Laboratory of Genomics Research Center, Academia Sinica, Taiwan. The U.S. Government (National Institutes of Health) approval was renewed on April 7, 2010 (Animal Welfare Assurance no. A3801-01) in accordance to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Revision; 2010).³⁶

Determination of Octanol–Buffer Partition Coefficients. The standard solutions of compound in MeOH at various concentrations of 1.0, 0.5, 0.1, 0.05, and 0.01 (mg/mL) were measured by HPLC (Agilent 1100 series) on an HC-C18 column (5 μ m porosity, 4.6 \times 250 mm) using MeOH/H₂O (1:1) as the eluent and UV detector at λ = 214 nm. The integral area of the peak corresponding to the compound was used (average of triple experiments) to establish a standard curve by Microsoft Excel.

To test compound partitioning, the respective test compounds (~1.0 mg) were placed in an Eppendorf tube, and octanol (0.75 mL) and phosphate buffer saline (0.75 mL of 0.01 M solution, pH 7.4) were added. The solution was equilibrated at 37 °C using magnetic stirring at 1200 rpm for 24 h. The octanol and aqueous phases were then separated by centrifugation at 6000 rpm for 5 min. Each sample (25 μ L) of aqueous layer was measured by HPLC. The concentration of drug in the aqueous phase was deduced by calibration with the above-established standard curve. Five replicates of each determination were carried out to assess reproducibility. From these data, the apparent octanol/buffer (pH 7.4) partition coefficient, $D_B = [Bt]_{oct}/[Bt]_{aq}$, is determined, where $[Bt]_{oct}$ and $[Bt]_{aq}$ are the concentrations of the drug in organic and aqueous phases, respectively.

LC/MS/MS Determination. Samples were separated with a Shimadzu liquid chromatograph separation system equipped with a DGU-20A3 degasser, a LC-20AD solvent delivery unit, a CBM-20A system controller, CTO-10ASVP column oven, and a CTC Analytics HTC PAL System. The samples (10 μ L) were separated on a preguarded Phenomenex Luna C18 column (5 μ , 2.0 \times 50 mm) with acetonitrile (A) and water (B) (both containing 0.1% formic acid) in a sequence of A/B 1:9 (0–2 min), 1:0 (2–2.3 min), and 1:9 (2.3–3.5 min) at 25 °C with an elution rate of 600 μ L/min.

For stability studies in gastric fluid and fresh human liver microsomes, and for pharmacokinetic studies with compounds in normal saline, the respective samples of rat plasma (100 μ L), mouse plasma (10 μ L), and microsomes (200 μ L) were chromatographically separated with a preguarded Waters Atlantis T3 3 μ m C18 (2.1 \times 100 mm) column. The mobile phase was CH₃CN/H₂O/HCO₂H (40:60:0.1, v/v/v).

Mass spectrometric analysis was performed using an API 3000 LC-MS/MS from Applied Biosystems Inc. (Canada) with an electrospray ionization (ESI) interface. Ionization was conducted in the positive mode, and the ion source temperature was maintained at 400 °C. High purity nitrogen gas was used as the collision-induced dissociation (CAD) gas, curtain gas, and nebulizer gas. Positive multiple reaction monitoring (MRM) mode was used for the quantification. The selected transitions of m/z were 321.1 $[M + H]^+ \rightarrow 174.2$ $[M - \text{pentyloxy} - \text{acetamide}]^+$ for compound 3a (collision energy, 31 eV), 349.3 $[M + H]^+ \rightarrow 261.2$ $[M - \text{pentyloxy}]^+$ for compound 3c (collision energy, 20 eV), 363.4 $[M + H]^+ \rightarrow 216.1$ $[M - \text{pentyloxy} - \text{acetamide}]^+$ for compound 4a (collision energy, 32 eV), and 391.3 $[M + H]^+ \rightarrow 303.3$ $[M - \text{pentyloxy}]^+$ for compound 4c (collision energy, 27 eV).

Stability of Compound in Simulated Gastric Fluid. To determine whether the test compound is likely to be stable in the stomach, a simulated gastric fluid (SGF, without enzymes) was prepared by dissolving 2 g of NaCl in 1 L of ddH₂O and adjusting the pH to 1.2 with HCl.³⁷ The test compound was incubated at a concentration of 2.5 mg/mL in the presence or absence of simulated gastric fluid for 30 min at room temperature. After 30 min, the samples were centrifuged for 10

min at 13 000g, and the supernatant was transferred to a plate for LC/MS/MS analysis. The experiment was performed in triplicates.

Metabolic Stability of Compound in Whole Blood and Microsomes. Human, dog, and rat whole blood samples were obtained from normal healthy individuals. Stock solutions of test compounds were prepared in dimethyl sulfoxide (DMSO) at the concentration of 1 mM and diluted to a final concentration of 500 μ M. Test compounds were incubated with whole blood at a final concentration of 5 μ M at 37 °C at 100 rpm on an orbital shaker. Aliquots were removed at 0, 15, 30, 45, 60, and 120 min, and the reaction was stopped by the addition of 5 volumes of cold methanol. After centrifugation at 20 000g for 20 min to precipitate protein, an aliquot of 200 μ L from the supernatant was used for LC/MS/MS analysis. All experiments were performed in duplicates.

Human, male dog, and male rat pooled liver microsomes were purchased from BD Biosciences and stored at –80 °C prior to use. A master solution containing 250 μ g of microsomes in 5.6 mM phosphate buffer and 5.6 mM MgCl₂ was prepared and mixed with test compounds or control solution (testosterone and midazolam) at the final concentration of 3 μ M. The mixture was prewarmed at 37 °C for 2 min, and then the reaction was started at 37 °C with the addition of 50 μ L of ultrapure H₂O (for negative control) or 10 mM NADPH solution at the final concentration of 1 mM. Aliquots of 50 μ L were removed from the reaction at 0, 10, 20, 30, and 60 min and stopped by the addition of 3 volumes of cold methanol. After centrifugation at 16 000 rpm for 10 min, an aliquot (100 μ L) of the supernatant was collected for LC/MS/MS analysis. All experiments were performed in duplicate. All calculations were carried out using Microsoft Excel 2003. The slope value, k , was determined by linear regression of the natural logarithm of the peak area of the parent drug vs incubation time curve. Peak areas were determined from extracted ion chromatograms. The in vitro half-life (in vitro $t_{1/2}$) was determined from the slope value: in vitro $t_{1/2} = -(0.693/k)$. Conversion of the in vitro $t_{1/2}$ (in min) into the in vitro intrinsic clearance (in vitro CL_{int} in μ L/min/mg proteins) was performed using the following equation (mean of duplicate determinations):

$$\text{in vitro CL}_{\text{int}} = (0.693/t_{1/2}) \times [\text{volume of incubation } (\mu\text{L}) / \text{amount of proteins (mg)}]$$

Other metabolic stability studies were conducted in five pooled fresh human liver microsomes. An incubation mixture containing test compound (80 ng/mL), phosphate buffer (0.1 M, pH = 7.4), MgCl₂ (5 mM), and NADPH regenerating solution (1 mM NADP⁺, 10 mM G6P, and 2 IU of G6PD) or UDPGA (2 mM) was vortexed well. The reaction mixture, in a final volume of 500 μ L, was preincubated for 1 min at 37 °C, and the human liver microsomes (0.5 mg/mL),³⁸ freshly prepared from five human livers obtained from the Department of Surgery, Tri-Service General Hospital (Taipei, Taiwan), were added to start the reaction. Each reaction was stopped at 5, 10, 15, 20, 30, 45, and 60 min by adding 500 μ L of cold acetonitrile. After termination of the incubation, oseltamivir (50 μ L, 40 ng/mL) was added as an internal standard for analysis. The sample was centrifuged, and 200 μ L aliquot was taken and evaporated to dryness under reduced pressure. The dried sample was reconstituted with 50% methanol for LC/MS/MS analysis. All experiments were performed in triplicates.

Pharmacokinetic Studies in Rats with Compounds in Normal Saline. All four compounds were administered as aqueous solutions in normal saline. Male rats were purchased from BioLASCO Taiwan Co., Ltd. The test compound was administered to six Sprague–Dawley rats (250–350 g) as a single intravenous (iv) dose (0.3–1 mg/kg of body weight) or as a single oral dose (1–5 mg/kg). At predetermined time points up to 24 h postdosing, blood samples were collected via a tail lateral vein, placed into heparinized tubes, and processed to extract the plasma, which was then stored at –20 °C. As an example of a representative sampling schedule, plasma samples were collected at 0.08, 0.17, 0.33, 0.67, 1, 2, 4, 6, 8, 10, 12, 16, and 24 h after administration of the iv dose to the rats and at 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 h after administration of the oral dose to the rats. The samples were extracted by Oasis MCX cartridge. The concentrations of compounds in the eluate were determined by LC/MS/MS analysis.

Pharmacokinetic Studies in Mice with Compounds in Normal Saline. The compounds were administered as aqueous solutions in normal saline. Male mice were purchased from BioLASCO Taiwan Co., Ltd. The compounds were administered to six mice as a single iv dose (0.25 mg/kg of body weight) or as a single oral dose (10 mg/kg). Plasma were prepared from tail lateral vein bleeds at 0.17, 0.33, 0.67, 1, 2, 4, 6, 8, 10, 12, and 24 h and then stored at -20°C . Deproteinized plasma samples were centrifuged for 10 min at 13 000g, and the supernatant was transferred to a plate for LC/MS/MS analysis. The concentrations of compound in the mice plasma samples were determined by LC/MS/MS analysis.

Pharmacokinetic Studies in Rats and Dogs with Compound Dissolved in 20% HP- β -CD in Water or in Microcrystalline Cellulose. Compound **4c** was prepared as aqueous solution in 20% 2-hydroxypropyl- β -cyclodextrin (HP- β -CD) in water or in microcrystalline cellulose. A sample of **4c** was administered to rats or dogs as a single iv dose (2 mg/kg and 5 mg/kg of body weight in rats and dogs, respectively) or as a single oral dose (50 mg/kg and 20 mg/kg in rats and dogs, respectively). Plasma samples were collected at 0.08, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, and 24 h after administration of the iv dose and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, and 24 h after administration of the oral dose. The concentrations of test compound in the rat and dog plasma samples were determined by LC/MS/MS analysis.

Pharmacokinetic Analysis. The pharmacokinetic parameters were obtained using a pharmacokinetic program WinNonlin, fitting data to a noncompartmental model. The pharmacokinetic parameters including the area under the plasma concentration-versus-time curve (AUC) to the last sampling time (AUC_{0-t}), to the time infinity ($\text{AUC}_{0-\infty}$), the terminal-phase half-life ($t_{1/2}$), the maximum concentration of compound in plasma (C_{max}), the time of C_{max} (T_{max}), the mean residence time (MRT), and the first-order rate constant associated with the terminal portion of the curve (k) were estimated via linear regression of time vs log concentration. The total plasma clearance (CL) was calculated as $\text{dose}/\text{AUC}_{\text{iv}}$, and the apparent volume of distribution (V_d) of drug administered iv was calculated as $\text{CL} \times k$. The oral bioavailability (F) of the test compound by oral administration was calculated from the $\text{AUC}_{0-\infty}$ of the oral dose divided by the $\text{AUC}_{0-\infty}$ of the iv dose.

Protein Binding Study. Plasma protein binding was determined using rapid equilibrium dialysis method.³⁹ Test compounds were prepared in DMSO at the concentration of 1 mM and diluted in series in 50% DMSO/ H_2O . Human, rat, or dog plasma was then spiked with the compound(s) at a final concentration of 1 μM with the final concentration of DMSO less than 1%. All compounds were tested in duplicates. Ranitidine and testosterone were included as the control compounds. A rapid equilibrium dialysis device in 96-well format with dialysis membrane of 8000 Da cutoff (Pierce) was used according to the manufacturer's instructions. Briefly, the base plate was rinsed with 20% ethanol for 10 min, followed by two rinses with ultrapure water. The base plate was then air-dried and used immediately. After the inserts were placed open-end-up into the wells of the base plate, 300 μL of phosphate buffer (pH 7.4) was added to the buffer chamber and 100 μL of spiked plasma sample was added into the sample chamber (indicated by a red ring). The device was then covered with a sealing tape and incubated at 37°C at approximately 100 rpm on an orbital shaker for 4 h. An aliquot of 50 μL from both buffer and plasma chambers were collected into separate microcentrifuge tubes. Fifty microliters of plasma was added to the aliquot from the buffer chamber while 50 μL of PBS was added to the collected plasma samples. A 300 μL amount of MeOH was then added to precipitate protein and release compound(s). After being vortexed and incubated for 30 min, the samples were centrifuged for 15 min at 16 000g, and the supernatant was transferred to a plate for LC/MS/MS analysis.

All calculations were carried out using Microsoft Excel 2003. The concentrations of test compounds in the buffer and plasma chambers were derived from the integrated area of the corresponding peak with known concentrations of the compounds as standards. The percentages of the bound fraction of the test compounds were calculated by the following equation:

$$\% \text{free} = \frac{(\text{concentration in buffer chamber})}{(\text{concentration in plasma chamber})} \times 100\%$$

$$\% \text{bound} = 100\% - \% \text{free}$$

Excretion Study of Compound 4c. A single oral dose (5 mg/kg) of compound **4c** was administered by gavage to six SD rats (average weight, 270 g). The rats were kept in metabolic cages, and their urine and feces were collected at 4, 8, 12, 24, and 48 h. The contents of compounds were determined by LC/MS/MS analysis.

■ ASSOCIATED CONTENT

● Supporting Information

Supplementary figures, tables, and NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*(J.M.F.) Tel: 8862-3366-1663. Fax: 8862-2363-7812. E-mail: jmfang@ntu.edu.tw. (O.Y.-P.H.) Tel: 8862-8792-3100 ext 18207. Fax: 8862-8792-4859. E-mail: hyp@ndmctsgh.edu.tw. (C.-H.W.) Tel: 8862-2789-9400. Fax 8862-2785-3852. E-mail: chwong@gate.sinica.edu.tw.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Academia Sinica, the National Science Council of Taiwan (grant NSC-98-2321-B-001-022), National Institute of Health of United States (NIH contract N01-AI-30063 to E.B.T.), and TaiMed Biologics for financial supports, as well as Dr. Donald F. Smee (Utah State University) and Mr. Shi-Chiang Li (National Defense Medical Center) for technical support.

■ ABBREVIATIONS USED

AUC, area under the concentration-versus-time curve; CL, clearance; CPE, cytopathic effect; CYP, cytochrome P 450; D , distribution coefficient; DMEM, Dulbecco's modified Eagle medium; EC_{50} , half maximal effective concentration; F (%), oral bioavailability (fraction absorbed); GOC, guanidino-oseltamivir carboxylic acid; GOS, guanidino-oseltamivir; HP- β -CD, 2-hydroxypropyl- β -cyclodextrin; HPLC, high-performance liquid chromatography; IC_{50} , half maximal inhibitory concentration; ip, intraperitoneal; iv, intravenous; LD_{50} , median lethal dose; MS, mass spectrometry; MDCK, Madin-Darby canine kidney; MRT, the mean residence time; NA, neuraminidase; OC, oseltamivir carboxylic acid; OS, oseltamivir; P , partition coefficient; SGF, simulated gastric fluid; TCID_{50} , 50% cell culture infectious dose; TP, tamiphosphor; TP1Et, tamiphosphor monoethyl ester; TP2Et, tamiphosphor diethyl ester; TPG, guanidino-tamiphosphor; TPG1Et, guanidino-tamiphosphor monoethyl ester; TPG2Et, guanidino-tamiphosphor diethyl ester; UDPGA, uridine 5'-diphosphoglucuronic acid; UGT, uridine 5'-diphosphoglucuronosyltransferase; ZA, zanamivir

■ REFERENCES

- (1) Schmidt, A. C. Antiviral therapy for influenza: a clinical and economic comparative review. *Drugs* **2004**, *64*, 2031–2046.
- (2) Moscona, A. Neuraminidase inhibitors for influenza. *N. Engl. J. Med.* **2005**, *353*, 1363–1373.
- (3) De Clercq, E. Antiviral agents active against influenza A viruses. *Nat. Rev. Drug Discovery* **2006**, *5*, 1015–1025.
- (4) Woods, J. M.; Bethell, R. C.; Coates, J. A.; Healy, N.; Hiscox, S. A.; Pearson, B. A.; Ryan, D. M.; Ticehurst, J.; Tilling, J.; Walcott, S. M. 4-

Guanidino-2,4-dideoxy-2,3-dehydro-*N*-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. *Antimicrob. Agents Chemother.* **1993**, *37*, 1473–1479.

(5) Dunn, C. J.; Goa, K. L. Zanamivir: a review of its use in influenza. *Drugs* **1999**, *58*, 761–784.

(6) Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Structure–activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. *J. Med. Chem.* **1998**, *41*, 2451–2460.

(7) McClellan, K.; Perry, C. M. Oseltamivir: a review of its use in influenza. *Drugs* **2001**, *61*, 263–283.

(8) Sidwell, R. W.; Smee, D. F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. *Expert Opin. Invest. Drugs* **2002**, *11*, 859–869.

(9) Jain, S.; Fry, A. M. Peramivir: another tool for influenza treatment? *Clin. Infect. Dis.* **2011**, *52*, 707–709.

(10) Kubo, S.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Yamashita, M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. *Antimicrob. Agents Chemother.* **2010**, *54*, 1256–1264.

(11) Ikematsu, H.; Kawai, N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. *Expert Rev. Anti-Infect. Ther.* **2011**, *9*, 851–857.

(12) Shie, J.-J.; Fang, J.-M.; Wang, S.-Y.; Tsai, K.-C.; Cheng, Y.-S. E.; Yang, A.-S.; Hsiao, S.-C.; Su, C.-Y.; Wong, C.-H. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. *J. Am. Chem. Soc.* **2007**, *129*, 11892–11893.

(13) Shie, J.-J.; Fang, J.-M.; Wong, C.-H. A concise and flexible synthesis of the potent anti-influenza agents tamiflu and tamiphosphor. *Angew. Chem., Int. Ed.* **2008**, *47*, 5788–5791.

(14) von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. *Nature* **1993**, *363*, 418–423.

(15) White, C. L.; Janakiraman, M. N.; Laver, G. W.; Philippon, C.; Vasella, A.; Air, G. M.; Luo, M. A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. *J. Mol. Biol.* **1995**, *245*, 623–634.

(16) Carbain, B.; Martin, S. R.; Collins, P. J.; Hitchcock, P. B.; Streicher, H. Galactose-conjugates of the oseltamivir pharmacophore – new tools for the characterization of influenza virus neuraminidases. *Org. Biomol. Chem.* **2009**, *7*, 2570–2575.

(17) Demmer, C. S.; Krogsgaard-Larsen, N.; Bunch, L. Review on modern advances of chemical methods for the introduction of a phosphonic acid group. *Chem. Rev.* **2011**, *111*, 7981–8006.

(18) Schug, K. A.; Lindner, W. Noncovalent binding between guanidinium and anionic groups: focus on biological- and synthetic-based arginine/guanidinium interactions with phosph[on]ate and sulf[on]ate residues. *Chem. Rev.* **2005**, *105*, 67–114.

(19) Proudfoot, J. R. The evolution of synthetic oral drug properties. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1087–1090.

(20) Straub, J. O. An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. *Ecotox. Environ. Safety* **2009**, *72*, 1625.

(21) Miller, J. M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G. L. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. *Mol. Pharm.* **2010**, *7*, 1223–1234.

(22) Liu, K.-C.; Lee, P.-S.; Wang, S.-Y.; Cheng, Y.-S. E.; Fang, J.-M.; Wong, C.-H. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir. *Bioorg. Med. Chem.* **2011**, *19*, 4796–4802.

(23) Li, W.; Escarpe, P. A.; Eisenberg, E. J.; Cundy, K. C.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lew, W.; Williams, M.; Zhang, L.; Kim, C. U.; Bischofberger, N.; Chen, M. S.; Mendel, D. B. Identification of GS4104

as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. *Antimicrob. Agents Chemother.* **1998**, *42*, 647–653.

(24) Koyama, K.; Takahashi, M.; Oitate, M.; Nakai, N.; Takakusa, H.; Miura, S.-i.; Okazaki, O. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. *Antimicrob. Agents Chemother.* **2009**, *53*, 4845–4851.

(25) Xie, G.; Nie, T.; Mackenzie, G. G.; Sun, Y.; Huang, L.; Ouyang, N.; Alsont, N.; Zhu, C.; Murray, O. T.; Constantinides, P. P.; Kopelovich, L.; Rigas, B. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. *Br. J. Pharmacol.* **2012**, *165*, 2152–2166.

(26) Widmer, N.; Meylan, P.; Ivanyuk, A.; Aouri, M.; Decosterd, L. A.; Buclin, T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. *Clin. Pharmacokinet.* **2010**, *49*, 741–765.

(27) Cass, L. M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled, or intranasal administration to healthy volunteers. *Clin. Pharmacol.* **1999**, *36* (Suppl), 1–11.

(28) Krise, J. P.; Stella, V. J. Prodrugs of phosphates, phosphonates, and phosphinates. *Adv. Drug Delivery Rev.* **1996**, *19*, 287–310.

(29) Sun, J.; Miller, J. M.; Beig, A.; Rozen, L.; Amidon, G. L.; Dahan, A. Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality. *Expert Opin. Drug Metab. Toxicol.* **2011**, *7*, 313–323.

(30) Boonyapiwat, B.; Sarisuta, N.; Kunastitchai, S. Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir. *Curr. Drug Delivery* **2011**, *8*, 392–397.

(31) Varghese Gupta, S.; Gupta, D.; Sun, J.; Dahan, A.; Tsume, Y.; Hilfinger, J.; Lee, K.-D.; Amidon, G. L. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. *Mol. Pharm.* **2011**, *8*, 2358–2367.

(32) Neumann, G.; Watanabe, T.; Ito, H.; Watanabe, S.; Goto, H.; Gao, P.; Hughes, M.; Perez, D. R.; Donis, R.; Hoffmann, E.; Hobom, G.; Kawaoka, Y. Generation of influenza A viruses entirely from cloned cDNAs. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 9345–9350.

(33) Fodor, E.; Devenish, L.; Engelhardt, O. G.; Palese, P.; Brownlee, G. G.; Garcia-Sastre, A. Rescue of influenza A virus from recombinant DNA. *J. Virol.* **1999**, *73*, 9679–9682.

(34) Reed, L. J.; Muench, H. A simple method of estimating fifty percent endpoints. *Am. J. Hyg.* **1938**, *27*, 493–497.

(35) Burleson, F. G.; Chambers, T. M.; Wiedbrauk, D. L. *Virology, a Laboratory Manual*; Academic Press: San Diego, CA, 1992.

(36) National Research Council. *Guide for the care and use of laboratory animals*; National Academy Press: Washington, DC, 1996.

(37) *United States Pharmacopeia and National Formulary*, 34th ed.; United States Pharmacopeial Convention Inc.: Rockville, MD, 2011.

(38) Guidance for Industry: Drug interaction studies: study design, data analysis and implications for dosing and labeling. <http://www.fda.gov/cder>. Draft published in September 2006 (accessed Oct 6, 2006).

(39) Waters, N. J.; Jones, R.; Williams, G.; Sohal, B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. *J. Pharm. Sci.* **2008**, *97*, 4586–4595.